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Beta-Blockers in
Syncope: The Jury Is Still Out
Madrid et al. (1) are to be commended for assessing the efficacy of
beta-blockers in neurocardiogenic syncope. Syncope is a common
problem, and beta-blockers are commonly used to attempt to treat
this disorder despite a paucity of randomized data.
Unfortunately, design limitations preclude this study from
providing definitive answers as to the role of beta-blocking drugs in
neurocardiogenic syncope. Previous papers have identified predic-
tors of beta-blocker success, including the presence of tachycardia
during the tilt table test, the need for isoproterenol to induce
syncope, and an acute response to beta-blockers (2,3). By including
a high percentage of tilt-negative patients (60%), the investigators
may have inadvertently diluted a potential treatment effect. The
researchers’ own data in their Figure 2 suggest a differential
response to study medication based upon the result of the tilt table
test. We agree with Madrid et al. (1) that tilt tests are not an ideal
diagnostic modality, but a better tool is not presently available. We
are now validating objective criteria quantitatively for the causes of
syncope that make use of a structured history to diagnose neuro-
cardiogenic syncope (1). Without such a tool, a positive tilt test
remains the diagnostic standard.
In the accompanying editorial to the Madrid et al. (1) article,
Dr. Sra (5) correctly points out that the assessment of therapy in
neurocardiogenic syncope is difficult. A single recurrence of syn-
cope is not an ideal end point due to symptom clusters and long
symptom-free periods. This problem is not unique to syncope
research; it is also seen in other disorders such as paroxysmal atrial
fibrillation. We have previously reported that the time to first
syncope recurrence after a positive tilt table test correlates very well
with the frequency of syncope after a positive tilt table test (6).
Time to first syncope recurrence is an appropriate end point for
such studies, but it can be supplemented with other end points
such as syncope burden and presyncope burden.
We agree with Dr. Sra (5) about the need for a large-scale
multicenter trial to answer the question of beta-blockers for
neurocardiogenic syncope. We are presently conducting a multi-
national, double-blind, placebo-controlled study of oral metoprolol
in patients with at least three lifetime episodes of neurocardiogenic
syncope and a positive head-up tilt table test. In the study, which
is funded by the Canadian Institutes of Health Research, we are
enrolling 220 patients, each of whom will be on blinded therapy for
one year. The primary end point is time to first syncope recurrence,
and secondary end points include the burden of syncope and
presyncope, and the quality of life over the full year.
Madrid et al. (1) may eventually be found to be correct in
concluding that atenolol specifically and beta-blockers in general
are not effective in decreasing or delaying symptoms in patients
with neurocardiogenic syncope. However, the final answer is not
yet known.
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REPLY
We appreciate the interest of Sheldon et al. in our article and the
opportunity to respond to his letter. We are aware of his concerns
regarding the methodology of our study, considering the diagnosis
of vasovagal syncope based on the typical clinical history. We do
not question the great clinical value of the tilt test, but in this
technified medicine we also need to consider the value of simple
things such as the anamnesis and physical examination. We
recognize the progress in the knowledge of physiology, which the
tilt test has rendered, but nevertheless it is not the gold standard
for the diagnosis of vasovagal syncope, with its limited sensitivity
and specificity and its dependence on the protocol.
In our study, only those patients with a clear anamnesis of
vasovagal syncope were included. In fact, more than 700 patients
with unexplained syncope were evaluated, and in the end only 50
patients were eligible for the study, including those patients with
clear clinical history of vasovagal syncope who were highly symp-
tomatic. A complete study to discard other possible causes of
syncope was carried out in all patients. Moreover, there was no new
etiological diagnosis of syncope during the follow-up (1). We want
to emphasize that despite the lack of efficacy of atenolol, the
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